{"paper_id": "c14c4b667373f5b598e0d1f4073121fac7b51fcb", "metadata": {"title": "Immortalization of Human B Cells: Analysis of B Cell Repertoire and Production of Human Monoclonal Antibodies", "authors": [{"first": "Elisabetta", "middle": [], "last": "Traggiai", "suffix": "", "affiliation": {}, "email": ""}]}, "abstract": [{"text": "One of the major challenges in human B cell immunology fi eld has been the objective to establish stable monoclonal cells lines that express the B cell receptor (BCR) on their cell surface and secrete antibodies. Such a system is extremely attractive not only for studying various aspect of BCR signaling but also for the generation of human monoclonal antibody and the analysis of the human B cell repertoire. This chapter describes an ef fi cient method to immortalize and clone human B cells by Epstein-Barr Virus (EBV) transformation.", "cite_spans": [], "ref_spans": [], "section": "Abstract"}], "body_text": [{"text": "In recent years, it has become evident that there is a great need to develop in vitro methods allowing to analyze human B cell responses in order to understand their regulation in normal as well as pathological situation such as autoimmune disorders, immunode fi ciency, and infection diseases ( 1 ) . One of the main limitations is that mature B cells, na\u00efve as well as memory, cannot be maintained ef fi ciently in vitro. When B cells are cultured in vitro in the presence of CD40 ligand (CD40L), cytokines, BCR triggering and Toll-like receptor (TLR) agonists they do respond. However, as soon as the B cells respond they differentiate into terminal plasma cells ( 2 ) . This process is accompanied by cell cycle arrest precluding the generation of long-term B cell lines. Recently, transduction of peripheral memory B cells with the transcriptional factors involved in the control of B cell proliferation and differentiation, B cell lymphoma-extra large (BCL-xl) and BCL-6, respectively, has allowed to immortalize and generate stable cell lines expressing BCR and are able to synthesize and secrete immunoglobulins ( 3 ) .", "cite_spans": [{"start": 294, "end": 299, "text": "( 1 )", "ref_id": null}, {"start": 666, "end": 671, "text": "( 2 )", "ref_id": null}, {"start": 1120, "end": 1125, "text": "( 3 )", "ref_id": null}], "ref_spans": [], "section": ""}, {"text": "Several approaches have been developed to dissect and investigate the molecular regulation of the human B cell repertoire. One successful method has been to combine immunoglobulin (Ig) gene repertoire analysis and Ig reactivity at the single cell level ( 4 ) . This strategy has been successfully applied for autoimmunity and immunode fi ciency questions, and for the fi rst time in human for central and peripheral B cell tolerance ( 5 ) .", "cite_spans": [{"start": 253, "end": 258, "text": "( 4 )", "ref_id": null}, {"start": 433, "end": 438, "text": "( 5 )", "ref_id": null}], "ref_spans": [], "section": ""}, {"text": "Among the oldest techniques to generate stable human B cell lines is the immortalization with EBV ( 6 ) . In the past, one of the major limitations was the very low ef fi ciency of B cell infection and subsequent cloning ( 7 ) . Thus, alternative methods to produce human monoclonal antibodies have been developed, such as immunization of transgenic mice expressing human Ig loci, phage display library, and humanization of mouse antibodies via genetic engineering (8) (9) (10) .", "cite_spans": [{"start": 221, "end": 226, "text": "( 7 )", "ref_id": null}, {"start": 465, "end": 468, "text": "(8)", "ref_id": null}, {"start": 469, "end": 472, "text": "(9)", "ref_id": null}, {"start": 473, "end": 477, "text": "(10)", "ref_id": null}], "ref_spans": [], "section": ""}, {"text": "We recently described an improved method to infect and immortalize human B cells with EBV, in the presence of the TLR9 agonist, CpG 2006, during viral transformation and cloning ( 11 ) . We have used this method to isolate neutralizing as well as nonneutralizing antibodies against severe acute respiratory syndrome coronavirus (SARS-CoV) ( 11 ) . These antibodies have been generated from one individual, who recovered from SARS infection. The obtained antibodies display a high in vitro potency to neutralize viral replication. This approach is not only applicable to the area of infectious diseases but also other clinical conditions, such as autoimmune diseases and cancer, and allows exploiting the breadth and the avidity of the human B cell repertoire ( 12, 13 ) . The method consists of four sequential steps: (a) human B cell subset isolation, (b) EBV infection, (c) B cell cloning, and (d) screening (Fig. 1 ). 5. 6-Well tissue culture plates.", "cite_spans": [{"start": 178, "end": 184, "text": "( 11 )", "ref_id": null}, {"start": 339, "end": 345, "text": "( 11 )", "ref_id": null}, {"start": 759, "end": 764, "text": "( 12,", "ref_id": "BIBREF30"}, {"start": 765, "end": 769, "text": "13 )", "ref_id": "BIBREF31"}], "ref_spans": [{"start": 910, "end": 917, "text": "(Fig. 1", "ref_id": null}], "section": ""}, {"text": "The human peripheral B cell pool is composed of cells at different stage of development, characterized by different signal requirements to differentiate into immunoglobulin secreting cells and carrying different Ig isotypes on the cell surface: (a) immature transitional 12. Centrifuge at 330 \u00d7 g for 10 min at 4\u00b0C and carefully remove the supernatants by aspiration.", "cite_spans": [], "ref_spans": [], "section": "B95.8 Cell Expansion Epstein-Barr Virus B Cell Infection"}, {"text": "13. Resuspend the pellet in 2 mL of PBS 2% FCS in 5 mL propylene conical tubes.", "cite_spans": [], "ref_spans": [], "section": "Count cells and adjust cell concentration"}, {"text": "14. After this step, cells are sorted according to B cell subset populations.", "cite_spans": [], "ref_spans": [], "section": "Count cells and adjust cell concentration"}, {"text": "15. Dilute mAbs in 400 mL of PBS 2% FCS to stain the cells (see Table 2 for the dilution factor). 22. Sort with a BD FACSAria according to the desired phenotype (see Note 3).", "cite_spans": [], "ref_spans": [{"start": 64, "end": 71, "text": "Table 2", "ref_id": "TABREF3"}], "section": "Count cells and adjust cell concentration"}, {"text": "1. Prewarm complete culture medium at 37\u00b0C.", "cite_spans": [], "ref_spans": [], "section": "Count cells and adjust cell concentration"}, {"text": "2. Thaw the cryo-preserved B95.8 cells by gently agitating the cryovial in a 37\u00b0C water bath.", "cite_spans": [], "ref_spans": [], "section": "Count cells and adjust cell concentration"}, {"text": "3. In a sterile tissue culture hood spray the vial with 70% ethanol.", "cite_spans": [], "ref_spans": [], "section": "Count cells and adjust cell concentration"}, {"text": "4. Very gently transfer the content of the vial in a 15 mL tube and add drop by drop up to 10 mL of warm complete medium.", "cite_spans": [], "ref_spans": [], "section": "Count cells and adjust cell concentration"}, {"text": "5. Centrifuge at 330 \u00d7 g per 10 min at room temperature (RT).", "cite_spans": [], "ref_spans": [], "section": "Count cells and adjust cell concentration"}, {"text": "6. Carefully aspirate the supernatants. Do not disturb the pellet.", "cite_spans": [], "ref_spans": [], "section": "Count cells and adjust cell concentration"}, {"text": "7. Resuspend the cells in warm complete culture medium and transfer them in a 6-well plates at 1 \u00d7 10 6 cell/mL. Monitor cells for growth (see Note 4). The screening strategy to select the \"good\" antibodies is a crucial part of the human antibody development. Humoral responses to vaccination or infection can be quantitatively but also qualitatively different. This re fl ects various level of protection in vivo, related to the differences in antibody function, which can be measured in vitro. All antibodies, which bind to a given antigen can be measured by enzyme-linked immunoabsorbent assay (ELISA).", "cite_spans": [], "ref_spans": [], "section": "Count cells and adjust cell concentration"}, {"text": "antibodies utilized to select B cells, such as anti-surface Ig could provide a signal to the B cell that can in fl uence the EBV infection. Indeed in all the antibodies combinations mentioned in Table 1 the surface Ig is used to negatively select the B cell population. Moreover, it is crucial to use anti-CD22 or CD20 microbeads to enrich B cells, instead of anti-CD19 microbeads. The latter induces the internalization of CD19 surface and consequently also of CD21, which is responsible for EBV entry into B cells ( 14 ) . 4 . Make sure that B95.8 do not grow in big clusters, some cells adhere to the plastic, and are intolerant to acid conditions. It is crucial to split them every 2 days with a 1/2 or 1/3 dilution factor. The goal is to gradually expand these cells to obtain the needed amount, which depends on the size of the infection you plan to perform. When the desired volume is reached, all cells maintenance procedures (including medium change) are stopped.", "cite_spans": [{"start": 516, "end": 522, "text": "( 14 )", "ref_id": "BIBREF32"}, {"start": 525, "end": 526, "text": "4", "ref_id": null}], "ref_spans": [{"start": 195, "end": 202, "text": "Table 1", "ref_id": "TABREF2"}], "section": "ELISA Screening"}], "bib_entries": {"BIBREF0": {"ref_id": "b0", "title": "Complete culture medium (see Subheading 2.1 )", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF1": {"ref_id": "b1", "title": "Sorted B cells (see Subheading 2.1 )", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF2": {"ref_id": "b2", "title": "TLR9 agonist (CpG 2006, 5 \u00a2 TCg TCg TTT TgT CgT TTT gTC gTT 3 \u00a2 (phosphotio bonds)) (Invivogen", "authors": [], "year": 2006, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF3": {"ref_id": "b3", "title": "EBV virus (see Subheading 2.2 )", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF5": {"ref_id": "b5", "title": "Ficoll-Hypaque density gradient", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF6": {"ref_id": "b6", "title": "Complete culture medium (see Subheading 2.1 )", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF7": {"ref_id": "b7", "title": "TLR9 agonist (CpG 2006, 5 \u00a2 TCg TCg TTT TgT CgT TTT gTC gTT", "authors": [], "year": 2006, "venue": "", "volume": "3", "issn": "", "pages": "", "other_ids": {}}, "BIBREF8": {"ref_id": "b8", "title": "Irradiated allogeneic PBMCs isolated from peripheral blood from normal donors", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF9": {"ref_id": "b9", "title": "EBV virus (see Subheading 2.2 )", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF10": {"ref_id": "b10", "title": "384-Well plates (Corning-Costar, Corning Incorporated Life Sciences", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF11": {"ref_id": "b11", "title": "Multichannel for 384 plates", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF12": {"ref_id": "b12", "title": "5, 15, and 50 mL propylene conical tubes (Falcon)", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF13": {"ref_id": "b13", "title": "Freezing media: 90% FCS, 10% DMSO", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF14": {"ref_id": "b14", "title": "Cryovials. 1. ELISA plates, medium binding", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF15": {"ref_id": "b15", "title": "Blocking solution: PBS 10% FCS", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF16": {"ref_id": "b16", "title": "Developing buffer: 1.59 g Na 2 CO 3 , 2.93 g NaHCO 3 , and 0.2 g NaN 3 in 1 L, pH 9", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF17": {"ref_id": "b17", "title": "ELISA substrate 104, conc. 1 mg/mL in developing buffer (cat. no. N2765, Sigma-Aldrich)", "authors": [], "year": null, "venue": "", "volume": "", "issn": "", "pages": "", "other_ids": {}}, "BIBREF19": {"ref_id": "b19", "title": "B-lymphocytes effector functions in health and disease", "authors": [{"first": "D", "middle": ["J"], "last": "References 1. Dilillo", "suffix": ""}, {"first": "M", "middle": [], "last": "Horikawa", "suffix": ""}, {"first": "T", "middle": ["F"], "last": "Tedder", "suffix": ""}], "year": 2011, "venue": "Immunol Res", "volume": "49", "issn": "", "pages": "281--292", "other_ids": {}}, "BIBREF20": {"ref_id": "b20", "title": "Characterization of a transitional preplasmablast population in the process of human B cell to plasma cell differentiation", "authors": [{"first": "M", "middle": [], "last": "Jourdan", "suffix": ""}, {"first": "A", "middle": [], "last": "Caraux", "suffix": ""}, {"first": "G", "middle": [], "last": "Caron", "suffix": ""}], "year": 2011, "venue": "J Immunol", "volume": "87", "issn": "", "pages": "3931--3941", "other_ids": {}}, "BIBREF21": {"ref_id": "b21", "title": "Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming", "authors": [{"first": "M", "middle": ["J"], "last": "Kwakkenbos", "suffix": ""}, {"first": "S", "middle": ["A"], "last": "Diehl", "suffix": ""}, {"first": "E", "middle": [], "last": "Yasuda", "suffix": ""}, {"first": "A", "middle": ["Q"], "last": "Bakker", "suffix": ""}, {"first": "Cmm", "middle": [], "last": "Van Geelen", "suffix": ""}, {"first": "M", "middle": ["V"], "last": "Lukens", "suffix": ""}, {"first": "G", "middle": ["M"], "last": "Van Bleek", "suffix": ""}, {"first": "M", "middle": ["N"], "last": "Widjojoatmodjo", "suffix": ""}, {"first": "Wmj", "middle": [], "last": "Bogers", "suffix": ""}, {"first": "H", "middle": [], "last": "Mei", "suffix": ""}, {"first": "A", "middle": [], "last": "Radbruch", "suffix": ""}, {"first": "F", "middle": ["A"], "last": "Scheeren", "suffix": ""}, {"first": "H", "middle": [], "last": "Spits", "suffix": ""}, {"first": "T", "middle": [], "last": "Beaumont", "suffix": ""}], "year": 2010, "venue": "Nat Med", "volume": "16", "issn": "", "pages": "123--129", "other_ids": {}}, "BIBREF22": {"ref_id": "b22", "title": "Ef fi cient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning", "authors": [{"first": "T", "middle": [], "last": "Tiller", "suffix": ""}, {"first": "E", "middle": [], "last": "Meffre", "suffix": ""}, {"first": "S", "middle": [], "last": "Yurasov", "suffix": ""}, {"first": "M", "middle": [], "last": "Tsuiji", "suffix": ""}, {"first": "M", "middle": ["C"], "last": "Nussenzweig", "suffix": ""}, {"first": "H", "middle": [], "last": "Wardemann", "suffix": ""}], "year": 2008, "venue": "J Immunol Methods", "volume": "329", "issn": "1-2", "pages": "112--124", "other_ids": {}}, "BIBREF23": {"ref_id": "b23", "title": "B-cell tolerance checkpoints in health and autoimmunity", "authors": [{"first": "E", "middle": [], "last": "Meffre", "suffix": ""}, {"first": "H", "middle": [], "last": "Wardemann", "suffix": ""}], "year": 2008, "venue": "Curr Opin Immunol", "volume": "20", "issn": "", "pages": "632--638", "other_ids": {}}, "BIBREF24": {"ref_id": "b24", "title": "EB virus-induced B lymphocyte cell lines producing speci fi c antibody", "authors": [{"first": "M", "middle": [], "last": "Steinitz", "suffix": ""}, {"first": "G", "middle": [], "last": "Klein", "suffix": ""}, {"first": "S", "middle": [], "last": "Koskimies", "suffix": ""}, {"first": "O", "middle": [], "last": "Makel", "suffix": ""}], "year": 1977, "venue": "Nature", "volume": "269", "issn": "", "pages": "420--422", "other_ids": {}}, "BIBREF25": {"ref_id": "b25", "title": "Requirements for the establishment of high-titered human monoclonal antibodies against tetanus toxoid using the Epstein-Barr virus technique", "authors": [{"first": "D", "middle": [], "last": "Kozbor", "suffix": ""}, {"first": "J", "middle": ["C"], "last": "Roder", "suffix": ""}], "year": 1981, "venue": "J Immunol", "volume": "127", "issn": "", "pages": "1275--1280", "other_ids": {}}, "BIBREF26": {"ref_id": "b26", "title": "Phage antibodies: fi lamentous phage displaying antibody variable domains", "authors": [{"first": "J", "middle": [], "last": "Mccafferty", "suffix": ""}, {"first": "A", "middle": ["D"], "last": "Grif Fi Ths", "suffix": ""}, {"first": "G", "middle": [], "last": "Winter", "suffix": ""}, {"first": "D", "middle": ["J"], "last": "Chiswell", "suffix": ""}], "year": 1990, "venue": "Nature", "volume": "348", "issn": "", "pages": "552--554", "other_ids": {}}, "BIBREF27": {"ref_id": "b27", "title": "Human antibodies from combinatorial libraries", "authors": [{"first": "D", "middle": ["R"], "last": "Burton", "suffix": ""}, {"first": "C", "middle": ["F"], "last": "Barbas", "suffix": ""}, {"first": "", "middle": [], "last": "Iii", "suffix": ""}], "year": 1994, "venue": "Adv Immunol", "volume": "57", "issn": "", "pages": "191--280", "other_ids": {}}, "BIBREF28": {"ref_id": "b28", "title": "Replacing the complementarity-determining regions in a human antibody with those from a mouse", "authors": [{"first": "P", "middle": ["T"], "last": "Jones", "suffix": ""}, {"first": "P", "middle": ["H"], "last": "Dear", "suffix": ""}, {"first": "J", "middle": [], "last": "Foote", "suffix": ""}, {"first": "M", "middle": ["S"], "last": "Neuberger", "suffix": ""}, {"first": "G", "middle": [], "last": "Winter", "suffix": ""}], "year": 1986, "venue": "Nature", "volume": "321", "issn": "", "pages": "522--525", "other_ids": {}}, "BIBREF29": {"ref_id": "b29", "title": "An ef fi cient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus", "authors": [{"first": "E", "middle": [], "last": "Traggiai", "suffix": ""}, {"first": "S", "middle": [], "last": "Becker", "suffix": ""}, {"first": "K", "middle": [], "last": "Subbarao", "suffix": ""}, {"first": "L", "middle": [], "last": "Kolesnikova", "suffix": ""}, {"first": "Y", "middle": [], "last": "Uematsu", "suffix": ""}, {"first": "M", "middle": ["R"], "last": "Gismondo", "suffix": ""}, {"first": "B", "middle": ["R"], "last": "Murphy", "suffix": ""}, {"first": "R", "middle": [], "last": "Rappuoli", "suffix": ""}, {"first": "A", "middle": [], "last": "Lanzavecchia", "suffix": ""}], "year": 2004, "venue": "Nat Med", "volume": "10", "issn": "", "pages": "871--875", "other_ids": {}}, "BIBREF30": {"ref_id": "b30", "title": "Generation of anti-NAG-2 mAb from patients' memory B cells: implications for a novel therapeutic strategy in systemic sclerosis", "authors": [{"first": "E", "middle": [], "last": "Traggiai", "suffix": ""}, {"first": "C", "middle": [], "last": "Lunardi", "suffix": ""}, {"first": "C", "middle": [], "last": "Bason", "suffix": ""}, {"first": "M", "middle": [], "last": "Dolcino", "suffix": ""}, {"first": "E", "middle": [], "last": "Tinazzi", "suffix": ""}, {"first": "R", "middle": [], "last": "Corrocher", "suffix": ""}, {"first": "A", "middle": [], "last": "Puccetti", "suffix": ""}], "year": 2010, "venue": "Int Immunol", "volume": "22", "issn": "5", "pages": "367--374", "other_ids": {}}, "BIBREF31": {"ref_id": "b31", "title": "Understanding and making use of human memory B cells", "authors": [{"first": "A", "middle": [], "last": "Lanzavecchia", "suffix": ""}, {"first": "N", "middle": [], "last": "Bernasconi", "suffix": ""}, {"first": "E", "middle": [], "last": "Traggiai", "suffix": ""}, {"first": "C", "middle": ["R"], "last": "Ruprecht", "suffix": ""}, {"first": "D", "middle": [], "last": "Corti", "suffix": ""}, {"first": "F", "middle": [], "last": "Sallusto", "suffix": ""}], "year": 2006, "venue": "Immunol Rev", "volume": "211", "issn": "", "pages": "303--309", "other_ids": {}}, "BIBREF32": {"ref_id": "b32", "title": "Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2", "authors": [{"first": "J", "middle": ["D"], "last": "Fingeroth", "suffix": ""}, {"first": "J", "middle": ["J"], "last": "Weis", "suffix": ""}, {"first": "T", "middle": ["F"], "last": "Tedder", "suffix": ""}, {"first": "J", "middle": ["L"], "last": "Strominger", "suffix": ""}, {"first": "P", "middle": ["A"], "last": "Biro", "suffix": ""}], "year": 1984, "venue": "Proc Natl Acad Sci U S A", "volume": "81", "issn": "", "pages": "4510--4514", "other_ids": {}}}, "ref_entries": {"FIGREF0": {"text": "MACS buffer: PBS, 0.5% bovine serum albumin (BSA), 2 mM EDTA, prepare fresh and keep on ice. 6. SuperMACS separator (Miltenyi Biotec). 7. Complete culture medium: RPMI 1640 (Gibco, Life Technologies, Carlsbad, CA, USA), sodium pyruvate (1 mM, Gibco), penicillin (100 U/mL, Gibco), streptomycin (100 m g/ mL, Gibco), kanamycin (100 m g/mL, Gibco), L -glutamine (2 mM, Gibco), nonessential amino acids (10 m M, Gibco), 2-beta-mercaptoethanol (5 \u00d7 10 \u22122 m M), 10% FCS (Hyclone, ThermoScienti fi c, Waltham, MA, USA). 8. LS column and LS column adaptor (Miltenyi Biotec.). 9. 5, 15, and 50 mL propylene conical tubes (Falcon, BD Biosciences, Franklin Lakes, NJ, USA). 10. Monoclonal antibodies for surface antigens to sort B cell subsets. 11. Refrigerated centrifuge. 12. Cell strainer, 40 m m (Falcon cat. no. 352340, BD Biosciences). 13. BD FACSAria Cell Sorter (BD Biosciences). 1. EBV Virus, produced from B95.8 cell line (Sigma Aldrich, St. Louis, MO, USA).2. Complete culture medium: RPMI 1640, sodium pyruvate (1 mM), penicillin (100 U/mL), streptomycin (100 m g/mL), kanamycin (100 m g/mL), L -glutamine (2 mM), nonessential amino acids (10 m M), 2-beta-mercaptoethanol (", "latex": null, "type": "figure"}, "FIGREF1": {"text": "Representation of the human peripheral B cell pool, which can be transformed by EBV. As soon as B Cell mature from the transtional stage to the haire and then the memory stage some of the functional properties as survival, proliferation, antibody production and class switch recombination increase.", "latex": null, "type": "figure"}, "FIGREF2": {"text": "65 m L of CD22 (or CD20) microbeads per 10 8 cells and incubate 30 min in the dark at 4\u00b0C. 4. Add 10 mL of cold MACS buffer and centrifuge at 330 \u00d7 g for 10 min, 4\u00b0C. Carefully remove the supernatants by aspiration. Make sure not to disturb the pellet. 5. Resuspend cells in 4 mL of cold MACS buffer at a concentration of 2 \u00d7 10 8 cells/mL. 6. Insert the LS column adaptor in the magnetic fi eld of the SuperMACS separator. Place the LS column into the adaptor and a 15 mL conical tube (see Note 2).", "latex": null, "type": "figure"}, "FIGREF3": {"text": "Prepare columns by rinsing with 4 mL cold MACS buffer. Discard the ef fl uent and change the collection tube. Make sure that the LS columns does not run dry. 8. Transfer the cell suspension to the column and let fl ow through. 9. Wash three times by adding 3 mL of MACS buffer, add new buffer when the column is empty. Collect the ef fl uent containing the B cell negative fraction. 10. Remove columns from the separator and place each on top of 15 mL propylene conical tubes. 11. Pipette 4 mL of cold MACS buffer onto columns. Flush the magnetically labeled cells by pushing the plunger into the column. Bring the volume of the cells to 10 mL with cold MACS buffer.", "latex": null, "type": "figure"}, "FIGREF4": {"text": "Centrifuge the 5 mL tube with the cells recovered from the enrichment, at 330 \u00d7 g per 10 min, 4\u00b0C. Remove supernatants carefully. 17. Add mAbs solution to the pellet, and dissociate into single cell suspension by pipetting. 18. Incubate for 20 min in the dark, at 4\u00b0C. 19. Add 4 mL PBS, 2% FCS and centrifuge at 330 \u00d7 g per 10 min. Repeat this once. 20. Resuspend cells in 0.5 mL PBS, 2% FCS and fi lter the cell suspension with a cell strainer (40 m m nylon) into a fresh 5 mL tube in order to eliminate cellular aggregates that could interfere with the sorting procedure.21. Prepare 15 mL collection tubes with 2 mL complete culture medium.", "latex": null, "type": "figure"}, "TABREF1": {"text": "Subsets from PBMC B cells, (b) na\u00efve B cells, (c) IgM memory B cells, and (d) switch memory B cells(Fig. 2 ). EBV can transform all peripheral resting B cell subsets. To immortalize the desired human B cell subset immunomagnetic beads enrichment followed by cell sorting are sequentially applied for puri fi cation. Enriched B cells can be labeled with different combinations of monoclonal antibodies speci fi c for surface antigens to identify and sort the B cell subpopulation of interest. A wide number of antibody combinations can be used and is summarized inTable 1.", "latex": null, "type": "table"}, "TABREF2": {"text": "", "latex": null, "type": "table"}, "TABREF3": {"text": "cells/mL. Dispense 50 mL of the cloning mixture with a multichannel pipette in 384-well plates. Different concentrations of B cells are plated at 25, 5, and 1 cells/well. 3. Complete medium with CpG 2006 2.5 mg/mL, 1% EBV, irradiated PBMCs at 2.5 \u00d7 10 5 cells/mL without sorted B cells are dispensed in two 384-well plates. These plates are the negative control plates to check for potential overgrowth of irradiated feeder cells. 4. Plates are transferred into the incubator at 37\u00b0C, 5% CO 2 .5. After 7 days, check cells with a microscope for growth.6. Supernatant of the growing clones is tested for the presence of the speci fi c antibody by a binding or functional assay.7. Speci fi c clones are expanded in complete culture medium, without CpG 2006 and EBV.8. As soon as the clones are growing, they can be frozen in 90% FCS, 10% DMSO. The minimum amount of EBV-B cells to be frozen is 5 \u00d7 10 6 per vial.", "latex": null, "type": "table"}}, "back_matter": [{"text": "Alternatively, if the speci fi c antigen can be expressed in the plasma membrane of a given cell line upon transfection of the relevant gene the binding of the antibody to the cell surface can be evaluated in fl ow cytometry. The ability to neutralize the speci fi c pathogen in vitro is another possible measurement of antibody function. 2. These columns separate 1 \u00d7 10 8 magnetically labeled cells from up to 10 9 . Smaller or larger column are also available.Alternatively an automated column separator (e.g., autoMACS, Miltenyi) can be used.3. In order to obtain a pure B cell population, it is necessary to use a positive selection method with immunomagnetic beads, followed by cell sorting. The positive selection method has the advantage that B cells are isolated with high degree of purity. However, unless Fab antibodies are used there is also the theoretical disadvantage that cells bearing high af fi nity Fc receptors (monocytes), may bind to the antibodies. In addition, the", "cite_spans": [], "ref_spans": [], "section": "annex"}]}